Martec/Egis Pharmaceuticals partnership
Executive Summary
Martec agreement with Budapest, Hungary-based firm provides the U.S. company with all pharmaceutical compounds developed by Egis over the next 13 years. Martec will have the exclusive right to market these compounds in the U.S., Canada and Mexico. Martec also will aid Egis in establishing a new R&D facility. Egis generates annual revenues of $ 175 mil., according to Martec.